Format

Send to

Choose Destination
Cytokine. 2015 Mar;72(1):86-96. doi: 10.1016/j.cyto.2014.12.006. Epub 2015 Jan 5.

Chemobrain: a critical review and causal hypothesis of link between cytokines and epigenetic reprogramming associated with chemotherapy.

Author information

1
School of Nursing, The University of Hong Kong, Hong Kong; Department of Anaesthesiology, The University of Hong Kong, Hong Kong. Electronic address: xmwang1@hku.hk.
2
National Institute of Nursing Research, National Institutes of Health (NIH), Bethesda, MD, USA.
3
School of Nursing, The University of Hong Kong, Hong Kong.
4
Department of Anaesthesiology, The University of Hong Kong, Hong Kong.
5
School of Chinese Medicine, The University of Hong Kong, Hong Kong, China.

Abstract

One consequence of modern cancer therapy is chemotherapy related cognitive dysfunction or "chemobrain", the subjective experience of cognitive deficits at any point during or following chemotherapy. Chemobrain, a well-established clinical syndrome, has become an increasing concern because the number of long-term cancer survivors is growing dramatically. There is strong evidence that correlates changes in peripheral cytokines with the development of chemobrain in commonly used chemotherapeutic drugs for different types of cancer. However, the mechanisms by which these cytokines elicit change in the central nervous system are still unclear. In this review, we hypothesize that the administration of chemotherapy agents initiates a cascade of biological changes, with short-lived alterations in the cytokine milieu inducing persistent epigenetic alterations. These epigenetic changes lead to changes in gene expression, alterations in metabolic activity and neuronal transmission that are responsible for generating the subjective experience of cognition. This speculative but testable hypothesis should help to gain a comprehensive understanding of the mechanism underlying cognitive dysfunction in cancer patients. Such knowledge is critical to identify pharmaceutical targets with the potential to prevent and treat cancer-treatment related cognitive dysfunction and similar disorders.

KEYWORDS:

Cancer chemotherapy; Chemobrain; Cognition dysfunction; Cytokines and epigenetics

PMID:
25573802
PMCID:
PMC4750385
DOI:
10.1016/j.cyto.2014.12.006
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center